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Brief CommunicationsFatal giant cell myocarditis after thymoma resection in myasthenia
gravis
Thomas M. Joudinaud, MD, PhD, Elie Fadel, MD, PhD, Vincent Thomas-de-Montpreville, MD, Sacha Mussot, MD,
Erwan M. Flecher, MD, and Phillippe G. Dartevelle, MD, Le Plessis Robinson, FranceMyasthenia gravis (MG) results in weakness andfatigability of skeletal muscles caused by an auto-immune-antibody reaction against acetylcholinereceptors at the neuromuscular junction. Treatment
includes anticholinesterase agents, thymectomy, and immunosup-
pression. Surgical thymectomy can induce remission or improve-
ment, allowing for reduction in immunosuppressive treatment.1
Although myocardial dysfunction is usually minimal in MG, thy-
moma can be associated with severe myocardial failure.2 We
report a rare case of fatal giant cell myocarditis (GCM) after a
thymoma resection in MG.
Clinical Summary
A 43-year-old man with no previous medical history was given a
diagnosis of MG. Thoracic computed tomographic scanning re-
vealed an anterior mediastinal tumor without superior vena caval
invasion on venography. Complete resection was performed
through a median sternotomy with resection of the anterior peri-
cardium, sparing both phrenic nerves. Histologic analysis revealed
an encapsulated thymoma extending in mediastinal fat. The patient
was discharged on day 5 after an uneventful recovery. One week
later, after a short episode of fever and diarrhea, the patient was
referred for severe dyspnea associated with hypoxia. Physical
examination showed an irregular tachycardia at 120 beats/min.
Electrocardiography showed diffuse low voltages and atrial fibril-
lation. Transthoracic echocardiography showed global hypokinesis
of both dilated ventricles. Coronary and pulmonary angiograms
ruled out myocardial infarction and massive pulmonary embolism.
Because of rapid hemodynamic deterioration, the patient was
intubated and ventilated, and inotropic support was administered.
Despite maximal medical treatment, the patient experienced car-
diogenic shock and was placed on circulatory support (extracor-
poreal membrane oxygenation), and a myocardial biopsy was
performed through the reopened sternotomy. The patient died from
severe multiorgan failure 18 hours later. The biopsy showed dif-
fuse myocardial necrosis with infiltration by lymphocytes, histio-
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GCM. Immunohistochemistry showed that lymphocytes were
mostly CD3 T cells and that histiocytes and giant cells were
CD68.
Discussion
Idiopathic GCM is a rare and usually fatal disease that affects
middle-aged men and women. Rapid progressive heart failure in
weeks or months associated with ventricular arrhythmia charac-
terizes the clinical course. Diagnosis is made on histology of the
myocardium obtained from myocardial biopsy or explanted
heart.2,3 We report the second case of GCM occurring after thy-
moma resection. Glennon and colleagues2 reported a patient who
had fatal cardiogenic shock with ventricular tachycardia resistant
to medical treatment 10 days after a thymoma resection. Postmor-
tem histology confirmed GCM. In both cases the severe course of
the fatal heart failure developed over a period of a few hours. In
contrast to our report, Glennon and colleagues did not describe any
autoimmune disorder in their patient. Although the majority of
GCM reported by Cooper and associates3 occurred in apparently
healthy persons, an association between GCM, thymoma, and/or
MG or other autoimmune disorders has been described in numer-
ous case reports over the last 50 years.2,3 MG is the most common
Figure 1. Histologic aspect of giant cell myocarditis obtained by
means of surgical biopsy. Myocytes appear degenerative. The
cellular infiltrate contains lymphocytes, histiocytes, and multinu-
cleated giant cells (arrows). (Hematoxylin and eosin stain, orig-
inal magnification 400.)parathymic syndrome (approximately 45% of patients having a
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Brief Communicationsthymoma), and 10% to 15% of patients with MG are found to have
a thymoma.1 An autoimmune mechanism dependant on CD4 T
lymphocytes is suspected to be responsible for the GCM, and
immunosuppressive therapy has been used to delay transplanta-
tion.3 Median survival or time to heart transplantation of 5 to 6
months had been reported in GCM.3 Ventricular assistance as a
bridge to heart transplantation was reported in patients who had
terminal heart failure within a week.4 Our patient, like the one
reported by Glennon and colleagues,2 presented in shock within
hours after the onset of symptoms, despite maximal medical treat-
ment. Both patients had no sign of active myocarditis before the
thymoma resection, and the operation might have in some way
triggered the disease. This very aggressive form of the disease after
a thymoma resection did not allow a premortem diagnosis and thus
the administration of appropriate immunotherapy or a ventricular
support device as a bridge to heart transplantation.3,4 Transplan-
tation remains the treatment of choice in the absence of recovery
of myocardial function with immunosuppressive agents, although
the disease is known to recur in the transplanted heart.3 Marelli andYung-Chie Lee, MD, PhD, Taipei, Taiwan
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The Journal of Thoraciwith biventricular assistance for 10 days and immunosuppressive
therapy with a follow-up of 3 years. Even if GCM appears to be a
very rare disease, this diagnosis should be considered in patients
who experience rapidly progressive heart failure after thymoma
resection. Although the possibility of massive pulmonary embo-
lism or myocardial infarction should not be ignored, early myo-
cardial biopsy might lead to the diagnosis. Appropriate immuno-
suppressive therapy and circulatory support as a bridge to
transplantation can be administrated.
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Using Surgicel to buttress the staple line in lung
volume reduction surgery for chronic obstructive
pulmonary disease
Jang-Ming Lee, MD, PhD, Jen-Deh Pan, MD, Wei-Cheng Lin, MD, andDr W. LeeAlthough effective for palliating the symptoms ofchronic obstructive pulmonary disease (COPD), lungvolume reduction surgery for COPD is highly vulner-able to postoperative major or persistent air leakage.1
Staple line reinforcement has been developed to prevent this
complication, including using polyglycolic acid,2 bovine pericar-
dial strips,3 or autologous parietal pleura.4 These materials either
carry a high cost2,3 or take a substantial amount of time for
preparation.4 A low-cost and easily available material for staple
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a new technique using oxidized regenerated cellulose (Surgicel,
Johnson & Johnson) for lung volume reduction surgery for COPD.
Clinical Summary
Patient 1. A 72-year-old man with COPD complained of
progressive exertional dyspnea unresponsive to bronchodilator
treatment. He had left pneumothorax and received a thoracoscopic
wedge resection on the pulmonary left upper lobe 4 years ago.
Chest computed tomography revealed diffuse emphysematous
change of the bilateral lung, especially in the right middle lobe. For
intractable dyspnea, video-assisted thoracic surgery for lung vol-
ume reduction surgery on the right lung was arranged. About 30%
of the pulmonary right upper lobe at the apex and 50% of the right
middle lobe at the basal portion was resected with a continuous
staple line (Figure 1, B, C, and D). Before the lung resection, a
strip of Surgicel, 4  8 cm, was tied on each site of the staple
(Figure 1, A). The working port on the anterior axillary line of the
fourth intercostal space was enlarged to 3 cm to prevent disloca-
tion of fixed Surgicel during staple introduction. A total of 7 sets
of Endo-GIA, 60  4.8 mm, and 2 sets of Endo-GIA, 45  4.8
mm, staples (Tyco Health Care, US Surgical) were used during the
operation. It took 2 hours for the e
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